Experts attending the ICS face various challenges when it comes to diagnosing IC/BPS, including the heterogeneity of symptoms and the lack of a standardized laboratory test. However, there have been recent developments in diagnostic methods, such as urine biomarker analysis, which could address these issues.

In my story, I encountered three changes that posed challenges to our lab's diagnostic efforts: inadequate handling and processing of urine samples collected at low temperatures, difficulty in collecting a large number of urine samples, and the need for a highly accurate diagnostic test.

To overcome these challenges, our lab implemented various solutions. Firstly, we developed a simple, reproducible, and cost-effective method for transporting and storing temperature-sensitive samples. This was achieved through a video demonstration that outlines the proper technique.

Watch video here

Secondly, we utilized crowdsourcing to collect a large number of urine samples while adhering to COVID-19 contact restrictions. We leveraged technology to maximize our limited budget and ensure a representative demographic makeup of study participants. This was achieved through a video demonstration that outlines the proper technique.

Watch video here

Lastly, we improved the accuracy of IC/BPS diagnosis by combining laboratory-based objective data and patient-reported outcomes using the Interstitial Cystitis Personalized Inflammation Symptom (IC-PIS) Score, which was developed through machine learning. This approach allowed for a more accurate and personalized diagnosis for each patient.

View Mike Chancellor's full bio here